CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · Real-Time Price · USD
1.360
+0.150 (12.40%)
At close: May 13, 2025, 4:00 PM
1.210
-0.150 (-11.03%)
Pre-market: May 14, 2025, 9:13 AM EDT
Company Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors.
The company’s lead drug candidate TPI 287 and Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma and other CNS malignancies.
CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc., Cortice Biosciences, Inc., and The University of Texas M.D.
Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
CNS Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Nov 8, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | John Climaco |
Contact Details
Address: 2100 West Loop South, Suite 900 Houston, Texas 77027 United States | |
| Phone | 800 946 9185 |
| Website | cnspharma.com |
Stock Details
| Ticker Symbol | CNSP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001729427 |
| CUSIP Number | 18978H409 |
| ISIN Number | US18978H4092 |
| Employer ID | 82-2318545 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John Michael Climaco Esq., J.D. | Chief Executive Officer, President and Director |
| Christopher S. Downs C.P.A., CTP, FP&A | Chief Financial Officer |
| Dr. Sandra L. Silberman M.D., Ph.D. | Chief Medical Officer |
| Dr. Waldemar Priebe Ph.D. | Founder |
| Dr. Donald H. Picker Ph.D. | Chief Science Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2025 | 424B4 | Prospectus |
| May 13, 2025 | EFFECT | Notice of Effectiveness |
| May 12, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 30, 2025 | 10-K/A | [Amend] Annual report |
| Apr 14, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 9, 2025 | 8-K | Current Report |
| Apr 7, 2025 | DRS | [Cover] Draft Registration Statement |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 20, 2025 | 424B5 | Filing |